Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration

We describe the preparation and the in vivo efficacy and safety of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) by the pulmonary and intramuscular routes. Nanoparticles showed 1-2 mg/L minimum inhibitory concentration against eight extensively drug-resistant P. aeruginosa strains. In vivo, SCM-NLC displayed significantly lower CFU/g lung than the saline and similar to that of the free SCM, even the dose in SCM-NLC group was lower than free SCM. There was not tissue damage related to the treatments. Biodistribution assessments showed a mild systemic absorption after nebulisation and a notorious absorption after IM route. Altogether, it could be concluded that SCM-NLC were effective against P. aeruginosa in vivo, not toxic and distribute efficiently to the lung and liver after pulmonary or intramuscular administrations.Graphical AbstractA novel formulation against different Pseudomans aeruginosa multiresistant clinical isolates based on sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) were developed, characterized and administered by pulmonary and intramuscular routes. In addition, the effectiveness, safety and biodistribution of SCM-NLC were tested against non-encapsulated SCM, using both in vitro and in vivo models. Encapsulation process enhances the pharmacological efficacy of SCM, decrease toxicity, and both administration routes result in an efficient therapy against P. aeruginosa: pulmonary route for maintenance therapy due to i...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research